Molina Maria, Fernández-Ruiz Mario, Gonzalez Esther, Cabrera Jimena, Praga Manuel, Rodriguez Alfredo, Tejido-Sánchez Angel, Medina-Polo Jose, Mateos Alonso, Rubio-Chacón Carlos, Sanchez Angel, Pla Ana, Andrés Amado
Department of Nephrology, Hospital Universitario "12 de Octubre", Madrid, Spain.
Department of Nephrology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Transplant Direct. 2024 May 28;10(6):e1649. doi: 10.1097/TXD.0000000000001649. eCollection 2024 Jun.
Uncontrolled donation after circulatory death (uDCD) increases organ availability for kidney transplantation (KT) at the expense of a higher risk of primary graft nonfunction (PNF). At least half of the cases of PNF are secondary to graft venous thrombosis. The potential benefit from prophylactic anticoagulation in this scenario remains unclear.
In this single-center retrospective study we compared 2 consecutive cohorts of KT from uDCD with increased (≥0.8) renal resistive index (RRI) in the Doppler ultrasound examination performed within the first 24-72 h after transplantation: 36 patients did not receive anticoagulation ("nonanticoagulation group") and 71 patients underwent prophylactic anticoagulation until normalization of RRI in follow-up Doppler examinations ("anticoagulation group").
Anticoagulation was initiated at a median of 2 d (interquartile range, 2-3) after transplantation and maintained for a median of 12 d (interquartile range, 7-18). In 4 patients (5.6%), anticoagulation had to be prematurely stopped because of the development of a hemorrhagic complication. In comparison with the nonanticoagulation group, recipients in the anticoagulation group had a lower 2-wk cumulative incidence of graft venous thrombosis (19.4% versus 0.0%; < 0.001) and PNF (19.4% versus 2.8%; = 0.006). The competing risk analysis with nonthrombotic causes of PNF as the competitive event confirmed the higher risk of graft thrombosis in the nonanticoagulation group = 0.0001). The anticoagulation group had a higher incidence of macroscopic hematuria (21.1% versus 5.6%; = 0.049) and blood transfusion requirements (39.4% versus 19.4%; = 0.050) compared with the nonanticoagulation group. No graft losses or deaths were attributable to complications potentially associated with anticoagulation.
Early initiation of prophylactic anticoagulation in selected KT recipients from uDCD with an early Doppler ultrasound RRI of ≥0.8 within the first 24-72 h may reduce the incidence of graft venous thrombosis as a cause of PNF.
心脏死亡后器官捐献(uDCD)在增加肾移植(KT)器官可用性的同时,会使原发性移植物无功能(PNF)风险升高。至少半数PNF病例继发于移植静脉血栓形成。在这种情况下预防性抗凝的潜在益处尚不清楚。
在这项单中心回顾性研究中,我们比较了2个连续队列的uDCD肾移植患者,这些患者在移植后最初24 - 72小时内进行的多普勒超声检查中肾阻力指数(RRI)升高(≥0.8):36例患者未接受抗凝治疗(“非抗凝组”),71例患者接受预防性抗凝治疗,直至随访多普勒检查中RRI恢复正常(“抗凝组”)。
抗凝治疗于移植后中位数2天(四分位间距,2 - 3天)开始,持续中位数12天(四分位间距,7 - 18天)。4例患者(5.6%)因出血并发症不得不提前停止抗凝治疗。与非抗凝组相比,抗凝组受者移植静脉血栓形成的2周累积发生率较低(19.4%对0.0%;P < 0.001),PNF发生率也较低(19.4%对2.8%;P = 0.006)。以PNF的非血栓性原因作为竞争事件的竞争风险分析证实了非抗凝组移植血栓形成风险更高(P = 0.0001)。与非抗凝组相比,抗凝组肉眼血尿发生率更高(21.1%对5.6%;P = 0.049),输血需求也更高(39.4%对19.4%;P = 0.050)。没有移植物丢失或死亡归因于可能与抗凝相关的并发症。
在移植后最初24 - 72小时内早期多普勒超声RRI≥0.8的特定uDCD肾移植受者中,早期开始预防性抗凝治疗可能会降低作为PNF原因的移植静脉血栓形成的发生率。